期刊文献+

乳腺癌组织学分级及预后因素分析 被引量:13

下载PDF
导出
摘要 目的 探讨浸润乳腺癌的组织学分级与预后的关系。方法 对256例浸润性导管癌(IDC)的临床和病理资料进行统计分析。结果 在256例IDE中,Ⅰ级、Ⅱ级和Ⅲ级的5年生存率分别为84.2%、70.2%和51.9%,3级之间有显著性差异(P<0.025);淋巴结转移阳性率分别为28.9%、56.1%和79.3%,3级之间有显著性差异(P<0.005);c-erbB-2阳性率分别为36.8%、60.2%和75.0%,3级之间有显著性差异(P<0.005)。结论 浸润性乳腺癌的组织学分级与5年生存率、淋巴结转移、c-erbB-2表达均密切相关,可作为判断乳腺癌预后的独立指标。
出处 《实用肿瘤学杂志》 CAS 2004年第5期357-358,共2页 Practical Oncology Journal
  • 相关文献

参考文献10

  • 1庞宗国,步宏.c-erbB-2基因在乳腺癌中的研究进展[J].中华病理学杂志,2000,29(4):313-314. 被引量:14
  • 2朱雄增,杨文涛,public8.sta.net.cn.当前乳腺癌诊治中的病理学新发展[J].中华病理学杂志,2000,29(3):165-167. 被引量:26
  • 3傅西林 见:刘复生 刘彤华 主编.乳腺恶性肿瘤[A].见:刘复生,刘彤华,主编.肿瘤病理学[C].北京,北京医科大学、中国协和医科大学联合出版社,1997.164.
  • 4Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology, 1995;27:219
  • 5world Health Organization. Histological typing of breast tumors. In: WHO. International histological classification of tumors. 2 nd ed. Geneva: World Helth Organization, 1981
  • 6Dougall WC, Qian X, Peterson NC, et al. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 1994;9:2109
  • 7Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987;235:177-182
  • 8Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991;19:403-410
  • 9Parham DM. Mitotic activity and histological grading of breast cancer. Pahtol Annu, 1995;30:189-207
  • 10刘志林,毛学正,马玉龙,赵志敏.乳腺癌雌、孕激素受体和c-erbB-2癌基因检测研究[J].临床与实验病理学杂志,1996,12(2):181-181. 被引量:6

二级参考文献7

  • 1Tang S C,J Clin Oncol,1999年,17卷,1710页
  • 2Penault-Llorca F,Adelaide J,Houvenaeghel G,et al.Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation[].Journal of Paleopathology.1994
  • 3Jacobs TW,Gown AM,Yaziji H,et al.Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer[].Journal of Clinical Oncology.1999
  • 4Pauletti G,Godolphin W,Press MF,et al.Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization[].Oncegene.1996
  • 5Jacobs TW,Gown AM,Yaziji H,et al.Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system[].Journal of Clinical Oncology.1999
  • 6Allred DC,Harvey JM,Berardo M,et al.Prognostic and predictive factors in breast cancer by immunohistochemical analysis[].Modern Pathology.1998
  • 7Andrulis DC,Bull SB,Blackstein ME,et al.Neu/erbB-2 amplification idetifies a poor-prognosis group of women with node-negative breast cancer.Toronto Breast Cancer Study Group[].Journal of Clinical Oncology.1998

共引文献50

同被引文献94

引证文献13

二级引证文献151

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部